23 C
Lucknow
March 5, 2024
The Hona News
health

Triplet therapy including belamaf prolongs survival in multiple myeloma



For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a study presented during the February 2024 session of the American Society for Clinical Oncology Plenary Series.



Source link

Related posts

CDC: Chronic fatigue syndrome prevalence 1.3 percent in 2021 to 2022

asdavi92

Wegovy: Why half of those taking it stop within a year, and what happens when they do

asdavi92

How can children, adolescents and adults who are overweight or obese be motivated to participate in health programs?

asdavi92

Leave a Comment